115 related articles for article (PubMed ID: 12126815)
21. Selective COX-2 inhibition.
Silas S; Clegg DO
Bull Rheum Dis; 1999; 48(2):1-4. PubMed ID: 12024416
[No Abstract] [Full Text] [Related]
22. Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
Epstein RA
Yale J Health Policy Law Ethics; 2005; 5(2):741-70. PubMed ID: 16052898
[No Abstract] [Full Text] [Related]
23. How safe are your prescription pills?
Gorman C
Time; 2001 Sep; 158(9):50-1. PubMed ID: 11550614
[No Abstract] [Full Text] [Related]
24. [Gastrointestinal complications caused by NSAIDs. Over 60% of arthrosis patients are endangered].
MMW Fortschr Med; 2003 Mar; 145(10):60. PubMed ID: 12688036
[No Abstract] [Full Text] [Related]
25. [Topical pharmacology. COX-2 inhibitors].
Heinzl S
Med Monatsschr Pharm; 1999 Oct; 22(10):298-304. PubMed ID: 10540801
[No Abstract] [Full Text] [Related]
26. [Clinical use of COX-2 inhibitors].
Ristić GG; Stefanović DZ
Vojnosanit Pregl; 2001; 58(3):283-95. PubMed ID: 11548555
[No Abstract] [Full Text] [Related]
27. COX-2 inhibitors--a lesson in unexpected problems.
Drazen JM
N Engl J Med; 2005 Mar; 352(11):1131-2. PubMed ID: 15713947
[No Abstract] [Full Text] [Related]
28. Differences between COX-2-specific inhibitors: clinical and economic implications.
Sonnenblick EH
Am J Manag Care; 2002 Oct; 8(15 Suppl):S428-30. PubMed ID: 12416792
[No Abstract] [Full Text] [Related]
29. Tailoring arthritis therapy in the wake of the NSAID crisis.
Olsen NJ
N Engl J Med; 2005 Jun; 352(25):2578-80. PubMed ID: 15972863
[No Abstract] [Full Text] [Related]
30. Use and misuse of the p-value.
Lesaffre E
Bull NYU Hosp Jt Dis; 2008; 66(2):146-9. PubMed ID: 18537787
[TBL] [Abstract][Full Text] [Related]
31. An update on specific COX-2 inhibitors: the COXIBs.
Gupta S; Crofford LJ
Bull Rheum Dis; 2001; 50(1):1-4. PubMed ID: 12092091
[No Abstract] [Full Text] [Related]
32. COX-2 inhibitors: better than ibuprofen for dental pain?
Dionne R
Compend Contin Educ Dent; 1999 Jun; 20(6):518-20, 522-4. PubMed ID: 10650365
[No Abstract] [Full Text] [Related]
33. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
Wynn RL
Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
[No Abstract] [Full Text] [Related]
34. COX-2 inhibitors and cardiovascular toxicity: a class effect?
Laible B
S D J Med; 2005 Mar; 58(3):93-4. PubMed ID: 15794479
[No Abstract] [Full Text] [Related]
35. The cox-2 inhibitors.
Strassels S
J Mass Dent Soc; 1999; 48(3):43-4. PubMed ID: 10808349
[No Abstract] [Full Text] [Related]
36. Non-steroidal anti-inflammatory drugs in orofacial pain management--an update.
van der Bijl P; van der Bijl P
SADJ; 2002 Aug; 57(8):328-31. PubMed ID: 12428528
[No Abstract] [Full Text] [Related]
37. [New anti-inflammatory analgetics--are they needed?].
Paakkari I
Duodecim; 1999; 115(20):2217-24. PubMed ID: 11973925
[No Abstract] [Full Text] [Related]
38. [Specific inhibitors of cyclooxygenase type 2] ].
Tomasová-Studýnková J
Vnitr Lek; 2002 May; 48(5):403-8. PubMed ID: 12061207
[TBL] [Abstract][Full Text] [Related]
39. Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases.
Gibofsky A
J Hypertens Suppl; 2002 Sep; 20(6):S25-30. PubMed ID: 12683424
[TBL] [Abstract][Full Text] [Related]
40. [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
Meyer CH
Klin Monbl Augenheilkd; 2005 Jan; 222(1):62-3. PubMed ID: 15678404
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
